Biomarqueurs émergents dans le cancer de prostate : à propos de la β-tubuline de classe III et du score urinaire PCA3

Biomarqueurs émergents dans le cancer de prostate : à propos de la β-tubuline de classe III et du score urinaire PCA3

Show other versions (1)

Pas de résumé français === Pas de résumé anglais

Bibliographic Details
Main Author:	Ploussard, Guillaume
Other Authors:	Paris Est
Language:	fr
Published:	2011
Subjects:	Béta-tubuline de classe III Cancer de prostate Docetaxel Chimiorésistance Pca3 Class III béta-tubulin Prostate cancer Chemoresistance
Online Access:	http://www.theses.fr/2011PEST0098/document

Similar Items

Biomarqueurs émergents dans le cancer de prostate : à propos de la β-tubuline de classe III et du score urinaire PCA3
by: Ploussard, Guillaume
Published: (2011)

Identification de SHISA3 comme gène médiateur de la transition épithélio-mésenchymateuse dans le cancer de la prostate résistant au docetaxel
by: Martin, Nicolas
Published: (2014)

Expression of Class III Beta-Tubulin Is Associated with Invasive Potential and Poor Prognosis in Thyroid Carcinoma
by: Hee Young Na, et al.
Published: (2020-11-01)

MiR-200c and HuR in ovarian cancer
by: Prislei Silvia, et al.
Published: (2013-02-01)

Value of PCA3 to Predict Biopsy Outcome and Its Potential Role in Selecting Patients for Multiparametric MRI
by: Peter F. A. Mulders, et al.
Published: (2013-05-01)

Bulge Cells of Rat Hair Follicles: Isolation, Cultivation, Morphological and Biological Features
by: Manouchehr Safari, et al.
Published: (2010-01-01)

Endothelial Cells Promote Docetaxel Resistance of Prostate Cancer Cells by Inducing ERG Expression and Activating Akt/mTOR Signaling Pathway
by: Wenhao Zhou, et al.
Published: (2020-12-01)

High expression of ladinin-1 (LAD1) predicts adverse outcomes: a new candidate docetaxel resistance gene for prostatic cancer (PCa)
by: Jianping Li, et al.
Published: (2021-01-01)

PCA3 score and prostate cancer diagnosis at repeated saturation biopsy. Which cut-off: 20 or 35?
by: Pietro Pepe, et al.
Published: (2012-08-01)

The role of taxanes in prostate cancer: literature review
by: A. K. Norsov, et al.
Published: (2018-07-01)

Docetaxel rechallenge in metastatic castration-resistant prostate cancer: A retrospective, single-center study
by: Seonggyu Byeon, et al.
Published: (2020-11-01)

Docetaxel in very elderly men with metastatic castration-resistant prostate cancer
by: Hui-Li Wong, et al.
Published: (2015-06-01)

Possibility of using PCA3 score without prostate massage in urine for diagnosing prostate cancer
by: A. A. Musaelyan, et al.
Published: (2021-02-01)

EP4 and Class III β-Tubulin Expression in Uterine Smooth Muscle Tumors: Implications for Prognosis and Treatment
by: Jocelyn Reader, et al.
Published: (2019-10-01)

Identification of morphological and molecular Aspergillus species isolated from patients based on beta-tubulin gene sequencing
by: Mahnaz Kheirkhah, et al.
Published: (2017-06-01)

Ductal prostate cancer
by: V. A. Biryukov, et al.
Published: (2016-05-01)

FUNCTIONAL TESTS OF β TUBULINS IN DROSOPHILA SPERM TAIL MORPHOLOGY
by: Washington, Ashley L.
Published: (2008)

Impactos do silenciamento do RNA não codificante PCA3 em células de câncer de próstata
by: Goulart, Ana Emília
Published: (2016)

شناسایی مورفولوژیک و ژنوتیپیک برخی جدایه‌های آسپرژیلوس محیطی در ایران بر اساس توالی ژن بتا توبولین (β-tubulin)
by: Gholamreza Shokohi, et al.
Published: (2012-02-01)

Design, Syntheses and Bioactivities of Androgen Receptor Targeted Taxane Analogs, Simplified Fluorescently Labeled Discodermolide Analogs, and Conformationally Constrained Discodermolide Analogs
by: Qi, Jun
Published: (2014)

In Vitro Trypanocidal Activity of Antibodies to Bacterially Expressed Trypanosoma brucei Tubulin
by: GW Lubega, et al.
Published: (2012-09-01)

In Vitro Trypanocidal Activity of Antibodies to Bacterially Expressed Trypanosoma brucei Tubulin
by: DP Kateete, et al.
Published: (2012-09-01)

Genetics and Expression Profile of the Tubulin Gene Superfamily in Breast Cancer Subtypes and Its Relation to Taxane Resistance
by: Babak Nami, et al.
Published: (2018-08-01)

Effectiveness of Docetaxel for Metastatic Hormone-sensitive Prostate Cancer in Clinical Practice
by: Maria Elisabeth Lendorf, et al.
Published: (2021-02-01)

Monotherapy with docetaxel in treatment of hormone resistant cancer of the prostate - our results
by: N K Mohanty, et al.
Published: (2003-01-01)

Docetaxel Enhances the Expression of STING Protein in PC3 Cells, and cGAMP Attenuates this Effect
by: Shaghayegh Salimi, et al.
Published: (2020-11-01)

Role of chemotherapy in prostate cancer
by: Rita Nader, et al.
Published: (2018-01-01)

Therapeutic efficacy of a novel βIII/βIV-tubulin inhibitor (VERU-111) in pancreatic cancer
by: Vivek K. Kashyap, et al.
Published: (2019-01-01)

Identification of predictive markers of the therapeutic effect of eribulin chemotherapy for locally advanced or metastatic breast cancer
by: Shinichiro Kashiwagi, et al.
Published: (2017-08-01)

Characterization of beta tubulin DNA sequences within the Candida parapsilosis complex
by: mahboobeh kharazi, et al.
Published: (2018-03-01)

Epithelial-Mesenchymal Transition in Docetaxel-Resistant Prostate Cancer
by: Camila Libardi do Amaral
Published: (2017-06-01)

Shikonin Reduces Growth of Docetaxel-Resistant Prostate Cancer Cells Mainly through Necroptosis
by: Sascha D. Markowitsch, et al.
Published: (2021-02-01)

Antiproliferative benzothiazoles incorporating a trimethoxyphenyl scaffold as novel colchicine site tubulin polymerisation inhibitors
by: Dong-Jun Fu, et al.
Published: (2020-01-01)

Relationship between Expression of β-tubulin-Ⅲ Plus Stathmin in Advanced Non-Small Cell Lung Cancer and its Sensitivity to Venorelbine Chemotherapy
by: Xiaolin PU, et al.
Published: (2009-01-01)

Abiraterone acetate and docetaxel with androgen deprivation therapy in high-volume metastatic hormone-sensitive prostate cancer in China: an indirect treatment comparison and cost analysis
by: Xin Hu, et al.
Published: (2019-12-01)

Metastatic Hormone-sensitive Prostate Cancer: Current Perspective on the Evolving Therapeutic Landscape
by: Hall ME, et al.
Published: (2020-04-01)

Successful use of docetaxel for emergency treatment of disseminated intravascular coagulation due to hormone-refractory metastatic prostate cancer
by: Serkan Keskin, et al.
Published: (2017-07-01)

A retrospective feasibility study of biweekly docetaxel in patients with high-risk metastatic castration-naïve prostate cancer
by: Sang Eun Yoon, et al.
Published: (2019-05-01)

Weekly low-dose docetaxel is an effective treatment with fewer adverse events for metastatic castration-resistant prostate cancer in Taiwanese patients
by: Cheng-Li Kao, et al.
Published: (2015-12-01)

Docetaxel-Loaded Nanoparticles Assembled from β-Cyclodextrin/Calixarene Giant Surfactants: Physicochemical Properties and Cytotoxic Effect in Prostate Cancer and Glioblastoma Cells
by: Laura Gallego-Yerga, et al.
Published: (2017-05-01)